文献速递呼吸衰竭与机械通气心脑血管急症

35岁及以下成人肺栓塞排除标准规则的失败率:RIETE登记研究结果

Failure rate of the pulmonary embolism rule-out criteria rule for adults 35 years or younger: Findings from the RIETE Registry.
PubMed 文献 · Acad Emerg Med · 2024-11-24
一句话结论在RIETE登记中,PERC-35规则排除肺栓塞的漏诊率为0.35%(95%CI上限0.40%),18-35岁亚组漏诊率7.0%(95%CI 6.0%-7.9%),作者认为若经前瞻性验证可减少年轻低验前概率患者的影像与辐射暴露。

本研究为基于RIETE登记(国际前瞻性、客观确诊静脉血栓栓塞症患者登记)的回顾性队列研究,旨在评估为≤35岁人群开发的PERC-35规则在减少不必要检查方面的失败率。在58,918例急性肺栓塞成人患者中,PERC-35规则的漏诊肺栓塞率为0.35%(n=204),95%CI上限0.40%;18-35岁亚组漏诊率为7.0%(95%CI 6.0%-7.9%)。与PERC-35阳性患者相比,PERC-35阴性患者更年轻(平均年龄28.4岁)、体重指数更低、妊娠/产后女性比例更高,慢性病更少,呼吸困难或晕厥更少而胸痛更多,D-二聚体和肌钙蛋白阳性率更低,大出血更少,肺栓塞/深静脉血栓复发率相似,抗凝期间无死亡。作者结论认为PERC-35规则在18-35岁患者中排除肺栓塞失败率低,若经前瞻性验证可减少低验前概率年轻患者的影像与辐射暴露。

要点

  • 在58,918例急性肺栓塞成人中,PERC-35规则总体漏诊肺栓塞率为0.35%(n=204),95%CI上限0.40%。
  • 18-35岁亚组采用PERC-35规则的漏诊率为7.0%(95%CI 6.0%-7.9%)。
  • PERC-35阴性患者平均年龄28.4岁,体重指数更低,妊娠/产后女性比例更高,慢性病显著更少。
  • PERC-35阴性患者呼吸困难或晕厥更少、胸痛更多,D-二聚体和肌钙蛋白阳性率更低。
  • PERC-35阴性患者大出血更少,肺栓塞/深静脉血栓复发率相似,抗凝期间无死亡。

适用人群与场景

  • RIETE登记中经客观确诊的急性肺栓塞成人患者,共58,918例;分析亚组为18-35岁患者。

诊断标准与关键阈值

  • PERC-35规则:为年龄≤35岁人群开发的肺栓塞排除规则,用于减少不必要的检查;PERC-35阴性(PERC-35N)与PERC-35阳性(PERC-35P)按该规则判定。

研究设计与关键结果

  • 研究类型:基于RIETE登记(国际前瞻性、客观确诊静脉血栓栓塞症患者登记)的回顾性队列研究;主要终点为采用PERC-35标准的漏诊肺栓塞率。
  • 58,918例急性肺栓塞成人中,PERC-35规则漏诊肺栓塞率为0.35%(n=204),95%CI上限0.40%;18-35岁亚组漏诊率为7.0%(95%CI 6.0%-7.9%)。
  • 与PERC-35P患者相比,PERC-35N患者更年轻(平均年龄28.4岁),体重指数更低,妊娠/产后女性比例更高。
  • PERC-35N患者慢性病发生率显著更低,表现为呼吸困难或晕厥更少、胸痛更多,D-二聚体和肌钙蛋白阳性率更低。
  • PERC-35N患者大出血事件更少,肺栓塞/深静脉血栓复发率相似,抗凝期间无死亡。

证据类型、等级与局限

  • 证据类型:基于国际前瞻性登记数据的回顾性队列研究;作者结论认为PERC-35规则在18-35岁患者中排除肺栓塞失败率低,若经前瞻性验证可减少低验前概率年轻患者的影像与辐射暴露。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,PERC-35规则在18-35岁患者中排除肺栓塞失败率低,若经前瞻性验证可减少低验前概率年轻患者的影像与辐射暴露。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The use of a computed tomography pulmonary angiogram to diagnose pulmonary embolism (PE) has increased, leading not only to higher PE diagnoses but also to overdiagnosis and unnecessary radiation exposure, even in young patients despite a lower PE incidence. The aim of this study was to assess the failure rate of the pulmonary embolism rule-out criteria 35 (PERC-35) rule developed to reduce unnecessary testing in individuals aged ≤35 years among patients included in the Registro Informatizado de la Enfermedad TromboEmbolica Venosa (RIETE) Registry.

METHODS: This retrospective cohort study used data from the RIETE Registry, an ongoing, international prospective registry of patients with objectively confirmed venous thromboembolism. The primary outcome was the missed PE rate using PERC-35 criteria. Secondary outcomes included the comparison of demographic and clinical characteristics, PE localization, treatment strategies, and outcomes between PERC-negative (PERC-35N) versus PERC-positive (PERC-35P) patients.

RESULTS: Of 58,918 adult patients with acute PE, the PERC-35 rule demonstrated a low missed PE rate of 0.35% (n = 204), with an upper 95% confidence interval [CI] of 0.40%. The missed rate was 7.0% (95% CI 6.0%-7.9%) in the 18- to 35-year subgroup. Compared to PERC-35P patients, PERC-35N patients were younger (mean age 28.4 years), with a lower body mass index, and included a higher proportion of pregnant/postpartum women. PERC-35N patients had a significantly lower rate of chronic diseases and presented less frequently with dyspnea or syncope but more often with chest pain. They showed lower rates of positive D-dimer and troponin levels. PERC-35N patients experienced fewer major bleeding episodes, similar recurrence rates of PE/deep vein thrombosis, and no deaths during anticoagulation.

CONCLUSIONS: The PERC-35 rule demonstrated a low failure rate to exclude PE in patients aged 18-35 years and could reduce imaging and radiation exposure in young patients with a low PE pretest probability if confirmed prospectively.

来源:Acad Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Jossein T, Mazzolai L, Lorenzo Hernández A, et al. Failure rate of the pulmonary embolism rule-out criteria rule for adults 35 years or younger: Findings from the RIETE Registry. Acad Emerg Med. 2024. PMID: 39582095. doi:10.1111/acem.15046

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。